Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
I PREVENT: Irbesartan in Hypertensive Diabetic Patients
NCT00362258Phase 4Completed
- Sponsor
- Sanofi
- Start
- Feb 2006
- Primary completion
- Sep 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of irbesartan in hypertension (HTN) and diabetic nephropathy (DN), sponsored by Sanofi. Primary endpoint: Proportion of patients reaching blood pressure target (130/80 mmHg). Started Feb 2006; status: completed.
02
Drugs
irbesartan
03
Conditions
hypertension (HTN)diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT00362258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00362258.